BR112022004697A2 - Variantes de cnp e conjugados das mesmas - Google Patents

Variantes de cnp e conjugados das mesmas

Info

Publication number
BR112022004697A2
BR112022004697A2 BR112022004697A BR112022004697A BR112022004697A2 BR 112022004697 A2 BR112022004697 A2 BR 112022004697A2 BR 112022004697 A BR112022004697 A BR 112022004697A BR 112022004697 A BR112022004697 A BR 112022004697A BR 112022004697 A2 BR112022004697 A2 BR 112022004697A2
Authority
BR
Brazil
Prior art keywords
cnp
variants
conjugates
present disclosure
generally relates
Prior art date
Application number
BR112022004697A
Other languages
English (en)
Inventor
J Wendt Daniel
Geoffrey Berguig
Jonathan Lebowitz
Karol Estrada
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of BR112022004697A2 publication Critical patent/BR112022004697A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

variantes de cnp e conjugados das mesmas. a presente divulgação refere-se, de modo geral, a variantes estáveis de peptídeo natriurético tipo c (cnp) e usos das mesmas para tratar distúrbios relacionados ao osso.
BR112022004697A 2019-09-16 2020-09-16 Variantes de cnp e conjugados das mesmas BR112022004697A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962901093P 2019-09-16 2019-09-16
US201962935050P 2019-11-13 2019-11-13
US202062963350P 2020-01-20 2020-01-20
US202062964852P 2020-01-23 2020-01-23
US202063038667P 2020-06-12 2020-06-12
PCT/US2020/051100 WO2021055497A1 (en) 2019-09-16 2020-09-16 Cnp variants and conjugates thereof

Publications (1)

Publication Number Publication Date
BR112022004697A2 true BR112022004697A2 (pt) 2022-06-14

Family

ID=72709850

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022004697A BR112022004697A2 (pt) 2019-09-16 2020-09-16 Variantes de cnp e conjugados das mesmas

Country Status (15)

Country Link
US (1) US20230192799A1 (pt)
EP (1) EP4031183A1 (pt)
JP (1) JP2022547723A (pt)
KR (1) KR20220063220A (pt)
CN (1) CN114616242A (pt)
AU (1) AU2020349493A1 (pt)
BR (1) BR112022004697A2 (pt)
CA (1) CA3153730A1 (pt)
CL (1) CL2023001727A1 (pt)
CO (1) CO2022004335A2 (pt)
IL (1) IL291179A (pt)
MX (1) MX2022003184A (pt)
PE (1) PE20220488A1 (pt)
TW (1) TW202124422A (pt)
WO (1) WO2021055497A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240035811A (ko) * 2021-07-09 2024-03-18 바이오마린 파머수티컬 인크. 소아의 골격 이형성증 치료를 위한 c-형 나트륨이뇨 펩티드 변이체
TW202334188A (zh) 2021-12-07 2023-09-01 美商拜奧馬林製藥公司 Ｃｎｐ療法
WO2023110758A1 (en) 2021-12-13 2023-06-22 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
WO2023117855A1 (en) * 2021-12-20 2023-06-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of analog of c-type natriuretic peptide for the treatment of fgfr-related bone repair and bone formation impairment
WO2023227505A1 (en) 2022-05-23 2023-11-30 Ascendis Pharma Growth Disorders A/S Liquid pharmaceutical formulations of cnp compounds
WO2024094747A1 (en) * 2022-11-02 2024-05-10 Novo Nordisk A/S Cnp compounds
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2073751T3 (es) 1990-04-20 1995-08-16 Hisayuki Matsuo Nuevo peptido con actividad fisiologica de origen porcino.
JP3026354B2 (ja) 1990-09-27 2000-03-27 壽之 松尾 ヒトｃｎｐ遺伝子及び前駆体蛋白
RU2573911C2 (ru) * 2009-05-20 2016-01-27 Байомарин Фармасьютикал Инк. Варианты натрийуретического пептида с-типа
JP6882256B2 (ja) * 2015-07-30 2021-06-02 バイオマリン ファーマシューティカル インコーポレイテッド 骨格異形成症を処置するためのｃ型ナトリウム利尿ペプチド変異体の使用
PL3400019T3 (pl) * 2016-01-08 2023-01-23 Ascendis Pharma Growth Disorders A/S Proleki cnp z przyłączeniem nośnika w ugrupowaniu pierścieniowy

Also Published As

Publication number Publication date
CA3153730A1 (en) 2021-03-25
CO2022004335A2 (es) 2022-08-30
TW202124422A (zh) 2021-07-01
CL2023001727A1 (es) 2024-01-12
AU2020349493A1 (en) 2022-04-07
US20230192799A1 (en) 2023-06-22
PE20220488A1 (es) 2022-04-04
WO2021055497A1 (en) 2021-03-25
KR20220063220A (ko) 2022-05-17
EP4031183A1 (en) 2022-07-27
MX2022003184A (es) 2022-06-23
IL291179A (en) 2022-05-01
JP2022547723A (ja) 2022-11-15
CN114616242A (zh) 2022-06-10

Similar Documents

Publication Publication Date Title
BR112022004697A2 (pt) Variantes de cnp e conjugados das mesmas
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
EP3735976A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
CO2018005306A2 (es) Variantes del factor viii reducido con cpg, composiciones y métodos y usos para el tratamiento de trastornos de la hemostasia
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
MX2019009117A (es) Anticuerpos anti alfa-sinucleina y usos de los mismos.
EP4019038A3 (en) Use of c-type natriuretic peptide variants to treat osteoarthritis
GT201600233A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
CO2018010504A2 (es) Inhibidores del enlace proteína-proteína de wdr5
GT201400222A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
CO2018009120A2 (es) Genes del factor viii optimizados
MX2023002973A (es) Uso de variantes de peptido natriuretico de tipo c para tratar displasia esqueletica.
TN2016000057A1 (en) Methods of treating sporadic inclusion body myositis
BR112019002646A2 (pt) composições de poxvírus quimérico e usos das mesmas
PE20210665A1 (es) Anticuerpos contra mica y/o micb y sus usos
PL412337A1 (pl) Wziernik nosowy
MX2020004600A (es) Constructos de oligonucleotidos y usos de estos.
MX2023005484A (es) Analogos de carbamoil fenilalaninol y usos de los mismos.
MX2021005346A (es) Constructos de suministro para transcitosis y metodos relacionados.
BR112022011902A2 (pt) Terapias de combinação
MX2021000555A (es) Tratamiento antidiabetico cardiovascular seguro.
NI202000071A (es) Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos
BR112022002720A2 (pt) Formulações de conjugados de benzazepinas e usos das mesmas
BR112017022682A2 (pt) construções de caliqueamicina e métodos de uso
PE20171320A1 (es) Analogos de calcitonina para tratar enfermedades y trastornos